Hints and tips:
...The BioNTech/Pfizer jab will be dispensed in “kid-sized” doses, a third of the size of those for people aged 12 years and more....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Scientists such as Sarah Gilbert, who developed the AstraZeneca jab, and the international authors of a recent paper in The Lancet are unconvinced....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Sarah Gilbert, a leader of the Oxford team, said its vaccine was stable at ordinary fridge temperatures of between 2C-8C....
...“Pfizer’s, Moderna’s and ours are not sufficient to vaccinate everyone around the world.”...
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Several other Covid-19 vaccines in development, including the Russian Sputnik-V and candidates from Johnson & Johnson of the US and CanSino of China, use adenoviruses....
...“It wasn't a mix-up in dosing,” Prof Sarah Gilbert, a leader of the Oxford vaccine project, told the FT. “It's quite usual to look at different dose levels when we do vaccine trials.”...
...Collectively the 30 companies, which includes General Motors, Qualcomm and Pfizer, own nearly $900bn in US debt and equities, according to an FT analysis of filings with the SEC....
...Tim Powell, partner at Powell Gilbert, the law firm that represented Actavis, said the case has “international implications” as other courts in Europe “are wrestling with the policy balance” of dealing with...
...Tim Powell, partner at Powell Gilbert, the law firm that represented Actavis, said the UK ruling provided “welcome clarity in a very complex area of the law”....
...Martin Gilbert, chief executive of Aberdeen Asset Management, a prominent institutional shareholder in AstraZeneca, had earlier said it was right for politicians to scrutinise the impact of any deal on the...
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
International Edition